• The Top Cardiology Trials of 2023

  • Dec 15 2023
  • Length: 35 mins
  • Podcast

The Top Cardiology Trials of 2023 cover art

The Top Cardiology Trials of 2023

  • Summary

  • For this year's review, Bob Harrington and Mike Gibson revisit the major cardiology conferences -- from ACC in New Orleans to AHA in Philly.

    This podcast is intended for healthcare professionals only.

    To read a transcript or to comment, visit:

    https://www.medscape.com/author/bob-harrington

    ACC 2023 Top Trials

    - Bempedoic Acid Cuts CV Events in Statin-Intolerant Patients: CLEAR Outcomes https://www.medscape.com/viewarticle/989100

    - Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients

    - Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616 https://www.jacc.org/doi/10.1016/j.jacc.2023.02.018

    ACC/WCC 2023 Collection Page https://www.medscape.com/viewcollection/36966

    ESC 2023 Top Trials

    - Wegovy Scores HFpEF Benefits in People With Obesity https://www.medscape.com/viewarticle/995844

    - Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity https://www.nejm.org/doi/full/10.1056/NEJMoa2306963

    - Acoramidis Shows Encouraging Results in ATTR Cardiomyopathy https://www.medscape.com/viewarticle/995883

    ESC 2023 Collection Page https://www.medscape.com/viewcollection/36988

    AHA 2023 Top Trials

    - Semaglutide 'A New Pathway' to CVD Risk Reduction: SELECT https://www.medscape.com/viewarticle/998373

    - Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes https://www.nejm.org/doi/full/10.1056/NEJMoa2307563

    -
    Bariatric Surgery is Associated With Improved Coronary Microvascular Function and Cardiorespiratory Fitness in Patients With Ischemia and Non-Obstructive Coronary Arteries https://www.ahajournals.org/doi/10.1161/circ.148.suppl_1.18949

    - Angioplasty Finally Proven Beneficial in Stable Angina: ORBITA-2 https://www.medscape.com/s/viewarticle/998375

    - A Placebo-Controlled Trial of Percutaneous Coronary Intervention for Stable Angina https://www.nejm.org/doi/full/10.1056/NEJMoa2310610

    - Impressive Bleeding Profile With Factor XI Inhibitor in AF: AZALEA https://www.medscape.com/viewarticle/998418

    - Promising First Results With DNA Editing to Lower LDL https://www.medscape.com/s/viewarticle/998719

    - Single Injection Reduces Blood Pressure for 6 Months: KARDIA-1 https://www.medscape.com/viewarticle/998666

    AHA 2023 Collection Page https://www.medscape.com/viewcollection/37277

    Other Mentions

    - N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects https://www.nejm.org/doi/full/10.1056/NEJMc2031173

    - Rimonabant: From RIO to Ban https://doi.org/10.1155%2F2011%2F432607

    - Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial https://doi.org/10.1016/S0140-6736(17)32714-9

    - Asundexian Phase 3 AF Study Halted for Lack of Efficacy https://www.medscape.com/viewarticle/998665

    - Challenges in the Design and Interpretation of Noninferiority Trials https://www.nejm.org/doi/full/10.1056/nejmra1510063

    - Milvexian for the Prevention of Venous Thromboembolism https://www.nejm.org/doi/full/10.1056/NEJMoa2113194

    You may also like:

    Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

    https://www.medscape.com/features/public/machine

    Hear John Mandrola, MD's summary and perspective on the top cardiology news each week, on This Week in Cardiology

    https://www.medscape.com/twic

    Questions or feedback, please contact news@medscape.net

    Show More Show Less

What listeners say about The Top Cardiology Trials of 2023

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.